Worsening anxiety and depression after initiation of lumacaftor/ivacaftor combination therapy in adolescent females with cystic fibrosis.

Autor: McKinzie CJ; Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, United States. Electronic address: cameron.mckinzie@unchealth.unc.edu., Goralski JL; Division of Pediatric Pulmonology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC, United States; Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, United States., Noah TL; Division of Pediatric Pulmonology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC, United States., Retsch-Bogart GZ; Division of Pediatric Pulmonology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC, United States., Prieur MB; Department of Psychiatry and Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC, United States.
Jazyk: angličtina
Zdroj: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society [J Cyst Fibros] 2017 Jul; Vol. 16 (4), pp. 525-527. Date of Electronic Publication: 2017 Jun 08.
DOI: 10.1016/j.jcf.2017.05.008
Abstrakt: In both phase III studies of LUM/IVA, as well as an extension study, worsening of mental health was not reported as a common side effect. Here we describe five cases in adolescent female patients that suggest a worsening of anxiety or depression associated with its use. In these five patients, two experienced suicidal ideation and three made suicide attempts that resulted in psychiatric hospitalizations.
(Copyright © 2017 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: